2025 Participating Companies - CEO and Investor Conference 2025

We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.

Loading

Loading

All
0 - 9
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Letter
- M

Madison Global Partners

United States
Madrona Venture Group/Bedford Ridge Capital

United States
Magdalena Biosciences, Inc.

United States

Biotech or pharma, therapeutic R&D
MAPREG

France

Biotech or pharma, therapeutic R&D
Matisse Pharmaceuticals B.V.

Netherlands

Biotech or pharma, therapeutic R&D
Mayo Clinic

United States

Diagnostics

Institute, hospital research

Medical device or technology

Other R&D services

Synthesis, analytic, diagnostic services
MBX Biosciences, Inc.

Biotech or pharma, therapeutic R&D
Medicovestor, Inc

United States

Biotech or pharma, therapeutic R&D
Melinta Therapeutics

United States

Biotech or pharma, therapeutic R&D
Meritage Technologies Inc.

1
2
3

Testimonials

It's the kind of meeting where biotech newsmakers can have productive dialogs with investors and other key players.

Luke Timmerman
The Timmerman Report
It's the caliber of attendees - biopharma companies on the verge of their next big step and investors looking for smart opportunities - that make BIO CEO & Investor Conference vital to the industry.

Anna Kazanchyan, MD
Founder & CEO, Saghmos Therapeutics
The BIO CEO & Investor Conference offers a collaborative forum where executives, investors and industry stakeholders can come together to learn and exchange ideas about innovation in the biopharma ecosystem.

Philip Ross, MD
Global Chairman, J.P. Morgan Healthcare Investment Banking
The BIO CEO & Investor Conference provides timely and relevant content on the issues driving the business of biotech, along with an invaluable platform for networking and partnering.

Chris Garabedian
Chairman and CEO, Xontogeny and Portfolio Manager, PXV Fund

Loading

Loading

Loading

Loading